Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2019-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is a single-site, 30 patient study for participants who have early stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). Funding Source - FDA OOPD and Foundation Fighting Blindness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

OCT in Diagnosis of Irregular Corneas

NCT03504800

Keratoconus Corneal Opacity Corneal Dystrophy

RECRUITING

A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.

NCT03101501

Presbyopia

TERMINATED PHASE4

Trial of the PresView Implant for the Improvement of Near Vision in Presbyopic Patients

NCT01933750

Presbyopia

COMPLETED NA

Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

NCT06411145

Neurotrophic Keratitis Neurotrophic Keratopathy Corneal Ulcer

WITHDRAWN PHASE4

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)

NCT04599933

Presbyopia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial is a prospective, randomized, double-masked, sham-controlled trial of 30 study participants who have early-stage retinitis pigmentosa, or Usher syndrome (type 2 or 3). The trial will be conducted at the University of California, San Francisco. Individuals with these diseases experience gradually worsening vision that ultimately may lead to blindness due to a genetic condition in which specialized cells in the eye's retina called photoreceptor cells cease functioning and/or die. The study is intended to use a relatively new, non-invasive technology called AOSLO (adaptive optics scanning laser ophthalmoscopy) in combination with a routine standard of care measurement called sdOCT (Spectral Domain Optical Coherence Tomography) to demonstrate that when a device that secretes an investigational drug called CNTF (Ciliary Neurotrophic Factor) is surgically placed in the patient's eye, one type of photoreceptor called "cone photoreceptors" is preserved such that the gradual loss of vision is halted.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinitis Pigmentosa Usher Syndrome Type 2 Usher Syndrome Type 3

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants are considered in screening upon signing of the consent. Enrollment does not occur until participant is deemed eligible, as per screening, and randomized for implant. As such, there were 22 total participants enrolled in the study. There was a participant who died prior to screening procedures being conducted of which was captured in the AE section as the death occurred after consent to enter screening period. However, this participant was not enrolled as they had not completed screening or randomization for implant.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NT-501

Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina

Group Type EXPERIMENTAL

NT-501

Intervention Type DRUG

Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.

Sham

Sham surgery

Group Type SHAM_COMPARATOR

Sham

Intervention Type PROCEDURE

Non-penetrating sham procedure to mimic implant procedure in the other eye.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NT-501

Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.

Intervention Type DRUG

Sham

Non-penetrating sham procedure to mimic implant procedure in the other eye.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CNTF, Encapsulated Cell Therapy, ECT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant must be between 18 and 55 years of age.
2. Participant must have a diagnosis of retinitis pigmentosa or Usher Syndrome type 2 or 3 (without profound deafness or cochlear implants).
3. Participant must understand and sign the protocol informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
4. Best-corrected visual acuity must be no worse than 20/63 (at least 59 letters).
5. Participants must have clear natural lenses.
6. Participants must have less than 6 diopters myopia.
7. Participants must be medically able to undergo ophthalmic surgery for the NT-501 device insertion and able to undergo all assessments and tests associated with the protocol.
8. Females of childbearing potential (women with last menses \<1 year prior to screening) must agree to use an effective form of birth control from study onset until they complete the study.
9. Participants must have reproducible baseline AOSLO image at 2 baseline imaging sessions with quality suitable to identify a minimum of 7 regions of interest (ROIs) at which reliable cone spacing and/or density measures can be made over the central 5.7 degrees.
10. Participants must have interocular symmetry of disease severity as measured by cone spacing, with a difference of less than 2 standard deviations in average cone spacing z-scores at the selected ROIs between the 2 eyes.
11. Participant's clinical diagnosis must be consistent with retinal degeneration in the set of retinitis pigmentosa (RP) dystrophies.

Exclusion Criteria

1. Participant is medically unable to comply with study procedures or follow-up visits.
2. Participant who has any of the following lens opacities: cortical opacity \> standard 3, posterior subcapsular opacity \> standard 3, or a nuclear opacity \> standard 3 as measured on the AREDS clinical lens grading system; or participant is pseudophakic or aphakic.
3. Participant has history of corneal opacification or lack of optical clarity.
4. Participant has undergone LASIK surgery or other refractive surgery for either eye.
5. Participant has nystagmus.
6. Participant has greater than 6 diopters myopia.
7. Participant has cystoid macular edema with cysts present within 4 degrees of the foveal center that prevent acquisition of at least 7 regions of interest with clear images of cone photoreceptors.
8. Participant has fewer than 7 regions of interest (ROIs) present on 2 baseline AOSLO image montages.
9. Participant has retinal vascular disease such as diabetic retinopathy or prior retinal vascular occlusive disease.
10. Participant has chronic requirement (e.g., ≥4 weeks at a time) for ocular medications or has disease(s) that in the judgment of the examining physician are vision threatening, toxic to the lens, retina, or optic nerve or may affect the primary outcome.
11. Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study.
12. Participant is receiving systemic steroids or other immunosuppressive medications.
13. Participant is currently participating in or has participated in any other clinical trial of a drug by ocular or systemic administration within the last 6 months.
14. Participant has previous exposure to an intra-ocular device or implant into the eye (excluding intra-ocular lens).
15. Participant has uveitis or other retinal inflammatory disease.
16. Participant has a history of myocardial infarction within the last 12 months.
17. Participant is pregnant or lactating.
18. Participant is considered immunodeficient or has a known history of HIV. A laboratory test for HIV will be performed, and a positive result is also an exclusion criterion.
19. Participant with a history of ocular herpes zoster.
20. Participant is on chemotherapy.
21. Participant has a history of malignancy, except study participant with cancer treated successfully ≥5 years prior to inclusion in the trial.
22. Participant with severe hearing disabilities in both ears.
23. Participant who has been diagnosed and treated for amblyopia as an infant.
24. Participant who, in the opinion of the study doctor, will not be a good study subject.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No